Interventional Glaucoma

Physicians are using the procedure to treat various stages of the disease.

According to the company, the outcomes reported demonstrate a favorable safety profile for its novel, noninvasive glaucoma treatment.

The device is an update on the previous iTrack canaloplasty device and features an ergonomic handpiece.

The first 2023 release of the Video Journal of Cataract, Refractive, & Glaucoma Surgery explores essential techniques for intraocular lens (IOL) removal, providing a diverse range of both routine and novel approaches within its hour-long presentation.

Brimonidine Tartrate Ophthalmic Solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma.

GAL-101 is a Phase 2/3-ready small molecule used to treat ophthalmic indications with high unmet medical need.

Ophthalmologists have discussions about driving with glaucoma patients.

Hurdles include limited space, handling thin sclera, choosing the right site.

The company’s MINIject is the only commercially available MIGS implant targeting the supraciliary space.

The researchers from Indiana University School of Medicine found neurons use mitochondria for a steady source of energy, and restoring mitochondrial homeostasis in the diseased neurons can protect the optic nerve cells from being damaged.

The Ergo-Series of the OMNI Surgical System maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures.

SBI-100 Ophthalmic Emulsion is a synthetic cannabinoid derivative to treat glaucoma and ocular hypertension.

During a presentation at the EnVision Summit Ophthalmology 2023 at El Conquistador Resort in Puerto Rico, Elena Bitrian, MD, outlines the challenges that surgeons are confronted with surgically in pediatric eyes, including the limited working space and palpebral fissure, axial length, and avoidance of the thin sclera and shallow scleral pass.

A recent clinical study demonstrates that low intracranial pressure correlates with impaired patient visibility, especially in the nasal zone.

Bonnie An Henderson, MD, founder and program director of EnVision Summit, previews what attendees can expect at this year’s meeting - from its diverse faculty to an inclusive Youth Program, while also giving back to the community. The conference will take place February 17 to 20 at the El Conquistador Resort in Fajardo, Puerto Rico.

Adrienne Graves, PhD, and Andrew Iwach, MD, co-founders of Glaucoma 360, share insights into the formation of the Glaucoma Research Foundation and what makes Glaucoma 360 such a unique conference.

A POSTECH research team has developed a wireless theranostic smart contact lens for monitoring and control of intraocular pressure in glaucoma.

Ruth Williams, MD, explained the importance of hypotension in glaucoma and its potential as a modifiable risk factor at the 27th annual Glaucoma Symposium during Glaucoma 360 at the Westin St. Francis San Francisco on Union Square.

Robert L. Stamper, MD, discusses some of the devices in development for measuring patients' intraocular pressure outside of doctors' office hours in his presentation at Glaucoma Research Foundation's annual Glaucoma Symposium.

L. Jay Katz, MD, provides some key takeaways from his Glaucoma 360 2023 presentation, "Steroid Induced Glaucoma Management."

Shan C. Lin, MD, provides an overview of the various intraocular lens technologies that are available, as well as considerations for contrast sensitivity and vision loss in patients at Glaucoma Research Foundation's annual Glaucoma Symposium.

Ying Han, MD, PhD, provides some key takeaways from her Glaucoma 360 2023 presentation, "Tube shunt update."

Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.

Kristen H. Ingenito, MBA, vice president and director of ophthalmics at Market Scope, discusses the volume of ophthalmologists offering interventional glaucoma treatment as well as emerging therapies in her presentation at the Glaucoma 360 New Horizons Forum.

According to the company, the approval allows Eyenuk’s EyeArt AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss.